Following rapid (and pricey) expansion efforts from Novo and Lilly, plus recent shortage updates at the FDA, “positive ...

Stagnant sales for Bristol Myers Squibb’s Sotyktu have raised questions about whether the tyrosine kinase 2 (TYK2) inhibitor ...

Undeterred by last year’s rejection and the recent approval of a close rival from Pfizer, Novo Nordisk has pushed its ...

That’s according to the Deloitte U.S. Center for Health Solutions, which found in a recent survey of 150 C-suite executives ...

The second and more recent probe involves alleged smuggling of unapproved drugs—the Daiichi-partnered HER2 therapy Enhertu ...

As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has ...

Christmas has come early for Eli Lilly this year, courtesy of a fresh FDA approval for the Indianapolis drugmaker’s obesity ...

Lexicon Pharmaceuticals has already thrown in the towel on its commercial efforts after a years-long uphill battle to get its ...

It’s been a year of big stories about Big Pharmas in the healthcare marketing world. | It’s been a year of big stories about ...

In a move that follows an increasingly common trend in biopharma M&A, Novartis is shedding sites and staffers from the German ...

The Vyndaqel family of drugs for the treatment of transthyretin amyloid cardiomyopathy is Pfizer’s fourth top-selling product ...

Viatris disclosed that its manufacturing facility in Indore, India, was issued a warning letter from the FDA, which banned 11 ...